References: |
Product Reference:
?A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643): A.A. Santilli, et al.; Experientia 30, 1110 (1974)
?The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes: D.E. Moody & J.K. Reddy; Am. J. Pathol. 90, 435 (1978)
?Peroxisome proliferation and hepatocarcinogenesis: M.S. Rao & J.K. Reddy; Carcinogenesis 8, 631 (1987)
?Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids: A. Schmidt, et al.; Mol. Endocrinol. 6, 1634 (1992)
?Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators: R.A. Roberts; Ann. N. Y. Acad. Sci. 804, 588 (1996) (Review)
?The PPARalpha-leukotriene B4pathway to inflammation control: P.R. Devchand, et al.; Nature 384, 39 (1996)
?Peroxisome proliferator-activated receptors a and g are activated by indomethacin and other non-steroidal anti-inflammatory drugs: J.M. Lehmann, et al.; J. Biol. Chem. 272, 3406 (1997)
?Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta: B.M. Forman, et al.; PNAS 94, 4312 (1997)
?Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators: B. Staels, et al.; Nature 393, 790 (1998)
?Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48: D. Lind |